Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

RIMA Senvest Loads Up Its Cannon With Marrone Bio Innovations Inc (MBII) As It Takes Aim At Big Returns

Page 1 of 2

Richard Mashaal‘s RIMA Senvest Management is one-of-a-kind hedge fund that is not afraid to go against the consensus opinion and employ contrarian investment strategies on companies that have lost favor among other investors. In a recent 13G filing, the fund increased its stake in one such company, Marrone Bio Innovations Inc (NASDAQ:MBII), to 1.30 million shares from a previous holding of 1.16 million. The new stake represents 5.34% of the company’s outstanding common stock. We’ll look at that move and briefly run down the fund’s top three micro-cap picks as of March 31 as well.



RIMA Senvest hunts for bargains on the stock market that have the potential to double or triple in value over the next one to three years. Founded in 1996, the fund’s annualized returns stood at 20.6% by the end of 2013. The fund’s performance in 2003 and 2009 was truly exceptional, when it generated returns of 169% and 229% in those years, respectively. However, the strategy backfired in 2008 as the fund incurred losses of 54%. The market value of the mid-sized fund’s public equity portfolio stood at $1.61 billion at the end of the first quarter. Most of Senvest’s holdings are in small companies and in the micro-cap category the top spots are occupied by Gain Capital Holdings Inc (NYSE:GCAP), Immersion Corporation (NASDAQ:IMMR), and YRC Worldwide Inc (NASDAQ:YRCW).

Senvest is a fund that we have been following for the last couple of years along with over 700 other investment firms. We follow hedge funds because our research has shown that their stock picks historically managed to generate alpha even though the filings are up to 45 days delayed. We used a 60-day delay in our back tests to be on the safe side and our research showed that the 15 most popular small-cap stocks among hedge funds outperformed the S&P 500 Total Return Index by an average of 95 basis points per month between 1999 and 2012. After adjusting for risk, our calculations revealed that these stocks’ monthly alpha was 80 basis points. We have also been sharing and tracking the performance of these stocks since the end of August 2012, during which time they have returned 144%, outperforming the S&P 500 ETF by nearly 85 percentage points (see more details here).

Coming back to Senvest’s holding in Marrone Bio Innovations Inc (NASDAQ:MBII), the fund initiated a holding in the $49.77 million provider of bio-based pest management and plant health products in the third quarter of 2014. The company’s stock has slumped by more than 60% since then. Since September last year, Marrone Bio Innovations Inc (NASDAQ:MBII) has been beleaguered by problems with its internal financial controls that date back to 2013. The company has also been facing a delisting possibility from the NASDAQ owing to its failure to file quarterly financial documents. However, in a recent letter to the company, The NASDAQ indicated that it will delay the delisting at least until a scheduled June 18 hearing. If the accounting issues end up getting resolved, something that Senvest is betting on, there is a considerable upside to Marrone Bio Innovations Inc (NASDAQ:MBII)’s stock price. Anand Parekh‘s Alyeska Investment Group is another stockholder of the company with 130,531 shares valued at $505,000.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!